DK1874781T3 - Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme - Google Patents

Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme

Info

Publication number
DK1874781T3
DK1874781T3 DK06743350T DK06743350T DK1874781T3 DK 1874781 T3 DK1874781 T3 DK 1874781T3 DK 06743350 T DK06743350 T DK 06743350T DK 06743350 T DK06743350 T DK 06743350T DK 1874781 T3 DK1874781 T3 DK 1874781T3
Authority
DK
Denmark
Prior art keywords
dihydrothienopyrimidines
treatment
inflammatory diseases
inflammatory
diseases
Prior art date
Application number
DK06743350T
Other languages
Danish (da)
English (en)
Inventor
Pascale Pouzet
Christoph Hoenke
Peter Nickolaus
Birgit Jung
Domnic Martyres
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Application granted granted Critical
Publication of DK1874781T3 publication Critical patent/DK1874781T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D521/00—Heterocyclic compounds containing unspecified hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK06743350T 2006-04-19 2006-04-19 Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme DK1874781T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005019201A DE102005019201A1 (de) 2006-04-19 2006-04-19 Neue Verbindungen zur Behandlung von entzündlichen Erkrankungen
PCT/EP2006/061680 WO2006111549A1 (de) 2005-04-21 2006-04-19 Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen

Publications (1)

Publication Number Publication Date
DK1874781T3 true DK1874781T3 (da) 2009-11-02

Family

ID=36678631

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06743350T DK1874781T3 (da) 2006-04-19 2006-04-19 Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme

Country Status (28)

Country Link
US (3) US7511045B2 (es)
EP (2) EP2060575A1 (es)
JP (1) JP5021624B2 (es)
KR (1) KR101335964B1 (es)
CN (1) CN101163706A (es)
AR (1) AR053235A1 (es)
AT (1) ATE434620T1 (es)
AU (1) AU2006237354B2 (es)
BR (1) BRPI0608387A2 (es)
CA (1) CA2605161A1 (es)
CY (1) CY1109348T1 (es)
DE (2) DE102005019201A1 (es)
DK (1) DK1874781T3 (es)
EA (1) EA013108B1 (es)
ES (1) ES2328400T3 (es)
HR (1) HRP20090395T1 (es)
IL (1) IL186749A (es)
MX (1) MX2007012313A (es)
NO (1) NO20074615L (es)
NZ (1) NZ563488A (es)
PL (1) PL1874781T3 (es)
PT (1) PT1874781E (es)
RS (1) RS51163B (es)
SI (1) SI1874781T1 (es)
TW (1) TWI380984B (es)
UA (1) UA93872C2 (es)
WO (1) WO2006111549A1 (es)
ZA (1) ZA200707591B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
SG171635A1 (en) * 2006-02-28 2011-06-29 Helicon Therapeutics Inc Therapeutic piperazines as pde4 inhibitors
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
BRPI0608387A2 (pt) 2006-04-19 2009-12-29 Boehringer Ingelheim Int compostos para o tratamento de doenças inflamatórias
RU2528340C2 (ru) * 2007-10-18 2014-09-10 Бёрингер Ингельхайм Интернациональ Гмбх ПОЛУЧЕНИЕ ДИГИДРОТИЕНО[3,2-d]ПИРИМИДИНОВ И ПРОМЕЖУТОЧНЫХ ПРОДУКТОВ, ПРИМЕНЯЮЩИХСЯ ДЛЯ ИХ СИНТЕЗА
BRPI0817781A2 (pt) * 2007-10-19 2019-09-24 Boehringer Ingelheim Int piperazino-diidroteinopirimidinas substituídas com heterociclo
US20110028441A1 (en) * 2007-10-19 2011-02-03 Boehringer Ingelheim International Gmbh Novel phenyl-substituted piperazino-dihydrothienopyrimidines
JP5563466B2 (ja) * 2007-10-19 2014-07-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ピペラジノ−ジヒドロチエノピリミジン誘導体
ES2381452T3 (es) 2007-10-19 2012-05-28 Boehringer Ingelheim International Gmbh PIPERIDINO-DIHIDROTIENOPIRIMIDINAS sustituidas
AU2008340421B2 (en) * 2007-12-21 2013-12-19 F. Hoffmann-La Roche Ag Heteroaryl derivatives as orexin receptor antagonists
US7923450B2 (en) 2008-01-11 2011-04-12 Hoffmann-La Roche Inc. Modulators for amyloid beta
CN101952275B (zh) 2008-02-22 2014-06-18 弗·哈夫曼-拉罗切有限公司 β-淀粉样蛋白的调节剂
EA019735B1 (ru) * 2008-05-13 2014-05-30 Бёрингер Ингельхайм Интернациональ Гмбх СИНТЕЗ ДИГИДРОТИЕНО[3,2-d]ПИРИМИДИНДИОЛОВ И СХОДНЫХ ПИРИМИДИНДИОЛОВ
CA2736924C (en) 2008-10-09 2016-06-28 F. Hoffmann-La Roche Ag Modulators for amyloid beta
KR101293421B1 (ko) 2008-11-10 2013-08-05 에프. 호프만-라 로슈 아게 헤테로사이클릭 감마 분비효소 조절제
CN102264705A (zh) 2008-12-24 2011-11-30 辛根塔有限公司 制备芳基酰胺的方法
JP2012519160A (ja) * 2009-02-27 2012-08-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅ４阻害剤及びｎｓａｉｄを含有する組み合わせ薬
US8592400B2 (en) 2009-02-27 2013-11-26 Boehringer Ingelheim International Gmbh Drug combinations containing PDE4 inhibitors and NSAIDs
UY32481A (es) * 2009-03-10 2010-09-30 Takeda Pharmaceutical Derivados de benzofurano
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
JP2014519519A (ja) * 2011-06-15 2014-08-14 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規３，４，４ａ，１０ｂ−テトラヒドロ−１Ｈ−チオピラノ［４，３−ｃ］イソキノリン化合物
WO2013019966A1 (en) * 2011-08-04 2013-02-07 Allergan, Inc. Aromatic bycyclic derivatives as cxcr4 receptor modulators
US9206195B2 (en) 2011-08-09 2015-12-08 Boehringer Ingelheim International Gmbh Dihydrothienopyrimidines
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
GB201203266D0 (en) 2012-02-24 2012-04-11 Randox Lab Ltd Assay for the detection of the phenylpiperazine family
US9499519B2 (en) 2012-12-26 2016-11-22 Medivation Technologies, Inc. Fused pyrimidine compounds and use thereof
EP2951161A1 (en) 2013-02-04 2015-12-09 Grünenthal GmbH 4-amino substituted condensed pyrimidine compounds as pde4 inhibitors
WO2014124860A1 (en) 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
CN108299400B (zh) 2013-03-14 2021-02-19 达特神经科学(开曼)有限公司 作为pde4抑制剂的取代的吡啶和取代的吡嗪化合物
CN104140426B (zh) * 2013-05-07 2017-02-01 上海汇伦生命科技有限公司 嘧啶并咪唑类化合物、其药物组合物及其制备方法和用途
CN103893183B (zh) * 2014-03-12 2016-02-10 中山大学 1-（2-氯苯基）-4-{噻吩并[3,2-d]嘧啶-4-基}哌嗪化合物在制备抗HIV-1病毒药物中应用
EP3226867A4 (en) * 2014-12-05 2018-05-09 Subramaniam Ananthan Heterocyclic compounds as biogenic amine transport modulators
CN111587112B (zh) * 2017-09-01 2023-10-10 卡德门企业有限公司 Rho相关含卷曲螺旋蛋白激酶的抑制剂
JP7216719B2 (ja) 2017-09-20 2023-02-01 ユニオン・セラピューティクス・アクティエセルスカブ 置換ジヒドロチエノピリミジンおよびホスホジエステラーゼ阻害剤としてのその使用
IL273169B2 (en) 2017-10-23 2024-05-01 Boehringer Ingelheim Int A new combination of active substances for the treatment of advanced lymphoid interstitial lung diseases
EP3724196B9 (en) 2017-12-15 2023-03-22 UNION therapeutics A/S Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors
ES2968824T3 (es) 2017-12-15 2024-05-14 Union Therapeutics As Tetrahidropirano dihidrotienopirimidinas sustituidas y su uso como inhibidores de la fosfodiesterasa
EP3724194B1 (en) 2017-12-15 2023-12-27 UNION therapeutics A/S Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
CN111285882B (zh) * 2018-12-07 2022-12-02 四川科伦博泰生物医药股份有限公司 稠环化合物、包含其的药物组合物及其制备方法和用途
CN113248518B (zh) * 2021-06-21 2022-03-25 山东大学 嘧啶哌嗪类衍生物及其制备方法与应用
MX2024006271A (es) 2021-12-09 2024-06-11 Boehringer Ingelheim Int Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
MX2024006270A (es) 2021-12-09 2024-06-11 Boehringer Ingelheim Int Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas.
WO2024032673A1 (zh) * 2022-08-09 2024-02-15 西藏海思科制药有限公司 Pde4b抑制剂及其用途
WO2024068386A1 (en) 2022-09-28 2024-04-04 Boehringer Ingelheim International Gmbh Use of biomarkers in the treatment of fibrotic conditions with a pde4b-inhibitor
WO2024067660A1 (zh) * 2022-09-29 2024-04-04 苏州爱科百发生物医药技术有限公司 氮杂稠环类化合物、其制备方法及其在医药上的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470336A1 (de) * 1962-07-04 1969-03-20 Thomae Gmbh Dr K Neue Dihydrothieno-[3,4-d]-pyrimidine und Verfahren zu ihrer Herstellung
NL122810C (es) * 1963-06-17
DE1470356A1 (de) * 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
NL123139C (es) 1965-03-31
DE1940572A1 (de) * 1969-08-08 1971-02-11 Thomae Gmbh Dr K Neue 2-Aminoalkylamino-thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
BE754606A (fr) * 1969-08-08 1971-02-08 Thomae Gmbh Dr K Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
DE2032687A1 (en) * 1970-07-02 1972-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Cardiovascular 2-aminoalkylamino-thienopyrimidines - and 4-morpholino derivatives from 4-diethanolamino-compounds by intramolecular cyclisa
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
FR2082496A5 (es) 1970-03-18 1971-12-10 Westinghouse Freins & Signaux
RO62428A (fr) * 1971-05-04 1978-01-15 Thomae Gmbh Dr K Procede pour la preparation des thyeno-(3,2-d)-pyrimidines
DE2121950A1 (en) * 1971-05-04 1972-11-23 Dr. Karl Thomae Gmbh, 7950 Biberach Thieno(3,2-d)pyrimidine derivs - with thrombocyte aggregation inhibiting activity
DE2750288A1 (de) * 1977-11-10 1979-05-17 Thomae Gmbh Dr K Neue 9-(omega-heteroarylamino- alkylamino)-erythromycine, ihre salze, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4256737A (en) 1979-06-11 1981-03-17 Syntex (U.S.A.) Inc. Long acting depot injectable formulations for LH-RH analogues
US4265738A (en) * 1979-10-25 1981-05-05 Goncharov Evgeny S Cleaning and/or grading machine for free-flowing materials
US5187168A (en) * 1991-10-24 1993-02-16 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
JPH07330777A (ja) * 1994-06-08 1995-12-19 Taisho Pharmaceut Co Ltd チエノ［３，２−ｄ］ピリミジン−４−オン誘導体
US6339089B2 (en) * 1997-08-13 2002-01-15 Fujirebio Inc. Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same
BR0114584A (pt) 2000-10-12 2003-08-26 Boehringer Ingelheim Pharma Monohidrato cristalino, processos para a sua preparação e sua aplicação para a preparação de um medicamento
DE10064994A1 (de) * 2000-12-23 2002-07-04 Merck Patent Gmbh Sulfamidothienopyrimidine
HUP0400333A3 (en) 2001-06-22 2012-10-29 Boehringer Ingelheim Pharma Crystalline anticholinergic, method for its production, and use thereof in the production of pharmaceutical composition
US6587548B2 (en) * 2001-07-17 2003-07-01 Hewlett-Packard Development Co., L.P. Method and system of using a single telephone number for multiple services
AU2002364211A1 (en) * 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
CA2472619A1 (en) * 2002-01-10 2003-07-24 Bayer Corporation Fused pyrimidine derivates as rho-kinase inhibitors
OA13050A (en) * 2003-04-29 2006-11-10 Pfizer Ltd 5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension.
MY141220A (en) * 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
WO2005082865A1 (ja) * 2004-02-27 2005-09-09 Astellas Pharma Inc. 縮合二環性ピリミジン誘導体
BRPI0608387A2 (pt) 2006-04-19 2009-12-29 Boehringer Ingelheim Int compostos para o tratamento de doenças inflamatórias

Also Published As

Publication number Publication date
PT1874781E (pt) 2009-07-27
NO20074615L (no) 2007-11-19
NZ563488A (en) 2010-04-30
CA2605161A1 (en) 2006-10-26
BRPI0608387A2 (pt) 2009-12-29
DE502006004066D1 (de) 2009-08-06
SI1874781T1 (sl) 2009-12-31
US20090186875A1 (en) 2009-07-23
UA93872C2 (ru) 2011-03-25
KR101335964B1 (ko) 2013-12-04
RS51163B (sr) 2010-10-31
AU2006237354A1 (en) 2006-10-26
WO2006111549A1 (de) 2006-10-26
ZA200707591B (en) 2009-08-26
HRP20090395T1 (hr) 2009-08-31
JP2008536890A (ja) 2008-09-11
KR20080004621A (ko) 2008-01-09
EP1874781B9 (de) 2010-09-08
IL186749A (en) 2014-08-31
EA013108B1 (ru) 2010-02-26
AR053235A1 (es) 2007-04-25
AU2006237354B2 (en) 2012-03-01
EP2060575A1 (de) 2009-05-20
IL186749A0 (en) 2008-02-09
EA200702200A1 (ru) 2008-04-28
PL1874781T3 (pl) 2009-12-31
US20070259846A1 (en) 2007-11-08
ATE434620T1 (de) 2009-07-15
US20100197656A1 (en) 2010-08-05
MX2007012313A (es) 2007-11-21
US7511045B2 (en) 2009-03-31
TWI380984B (zh) 2013-01-01
EP1874781B1 (de) 2009-06-24
ES2328400T3 (es) 2009-11-12
CN101163706A (zh) 2008-04-16
DE102005019201A1 (de) 2006-11-02
CY1109348T1 (el) 2014-07-02
JP5021624B2 (ja) 2012-09-12
US7723341B2 (en) 2010-05-25
EP1874781A1 (de) 2008-01-09
US8354531B2 (en) 2013-01-15

Similar Documents

Publication Publication Date Title
DK1874781T3 (da) Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
DK2056807T3 (da) Behandling af inflammatoriske sygdomme
DK2474321T3 (da) Sammensætninger til behandling af collagenmedierede sygdomme
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
DK2478907T3 (da) Sammensætninger til behandling af kræft
DK2086944T3 (da) Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater
DK2056842T3 (da) Modificeret galactosylceramid til behandling af cancerøse sygdomme
DK3354276T3 (da) Sammensætninger til behandlingen af gastrointestinal inflammation
FR2896407B3 (fr) Ambulateur
SMAP200900085A (it) 3-imidazolil-indoli per il trattamento di malattieproliferative
DK2285808T3 (da) Spiroindolderivater til behandling af parasitsygdomme
DK2445912T3 (da) Ny forbindelse anvendelig til behandlingen af degenerative og inflammatoriske sygdomme
DK1948615T3 (da) Til behandling af gynækologiske sygdomme egnede pyrazolderivater
DK2004204T3 (da) Behandling af neurodegenerative sygdomme med selenat
DK2035369T3 (da) Terapeutiske
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
DK2209784T3 (da) Forbindelser til behandling af hepatitis C
DK2107870T3 (da) Lavement med reduceret irritationseffekt til behandling af inflammatorisk tarmsygdom
DK1896077T3 (da) Fremgangsmåder og sammensætninger til forebyggelse og behandling af inflammatoriske sygdomme
DK2099446T3 (da) Fremgangsmåde til behandling af inflammatorisk tarmsygdom
DK2022504T3 (da) Salve til behandling af hæmorider
DK2012814T3 (da) Fremgangsmåder til behandling af autoimmunsygdomme
DK2296651T3 (da) 5-hydroxymethyl-oxazolidin-2-on-derivater til behandling af bakterielle intestinale sygdomme
DK2109449T3 (da) Lægemiddel til behandling af endometriose